Pfizer's Inlyta Reconsidered By NICE And Recommended
New VBID Research Offers 'Compelling' Data But Reinforces Long-Term Prospects
How Much Is Patients' Time Worth?
Four Ways To Assure Americans Get High Quality Care Despite Narrow Networks.
Managed Care Digest Series - SANOFI
ISPOR Board Of Directors - Election 2014 - Cast Your Vote!
Getting Real With Real World Evidence
Webinar - Patient Reported Outcomes - Now Available On Demand!
ERT Named Preferred Provider Of Key Quality Of Life Assessments
Medicaid Health Plans Need to Cozy Up to PBMs
Rising costs and increasing use of specialty pharmaceuticals are a big concern among Health Plans. Javier Menendez, RPh, associate vice president of pharmacy operations at Virginia Premier Health Plan, Inc., recently spoke at the Leadership Summit on Medicaid Managed Care, and said recent drug approvals would only increase the costs. He suggested that health plans pay close attention to their relationship with PBMs. More here. (Source: First Report Managed Care, 2/27/2014)
Avella study finds that pharmacist intervention saves almost $30,000 monthly
Medication non-adherence impacts clinical outcomes and contributes to rising costs. Avella, in partnership with the University of Arizona and the NIH, conducted a research study that reveals the impact of specific medication adherence strategies. The study sample included renal transplant recipients who were at least one year post-transplant and served by Avella. View their findings here. (Source: Avella, 2/27/2014)
Did you pass? BPS Announces Results of 2013 Exams
The Board of Pharmacy Specialties® (BPS) has announced results of the 2013 BPS specialty certification and recertification exams. A total of 3,247 pharmacists passed the exams in the six specialties currently offered by BPS: ambulatory care pharmacy, nuclear pharmacy, nutrition support pharmacy, oncology pharmacy, psychiatric pharmacy and pharmacotherapy. There are now 19,109 BPS board certified pharmacists, which represents an increase of almost 21% from 2012. Read more here. (Source: News-Line, March 2014)
ISPOR's News Across Central & Eastern Europe
How A Performance Threshold Increase Affected General Practitioner Behavior in Scotland
First Drug Assessed By NICE's Highly Specialised Technologies Programme
NEW! Medical Device and Diagnostics Road Map Information for South Korea
NEW!! ISPOR Task Force Review Groups Available
Significant Adherence Improvement & Cost Savings With Avella's Adherence Toolbox
Patient Assistance Programs - Added Cost Or Strategic Advantage?
Express Scripts Drug Trend Report
Rating The Quality Of Observational Studies Of Comparative Effectiveness
Marketing- How Does Your Company Stand Out From The Rest?
Healthcare Trends & Forcasts - Don't Miss Out On This Vital Resource!
Healthcare Trends & Forcasts - Don't Miss Out On This Vital Resource!
Analysis Aims To Better Understand The FDA
NICE Technology Appraisal Methods - What Changes Can You Expect?
NICE Technology Appraisal Methods - What Changes Can You Expect?
NICE Approves Bayer's Eylea For New Use
EMD Serono Specialty Digest, 9th Edition
CVS/Caremark Insights Drug Trend Report 2013
Three Things You Need To Know About Big Data
Three Things You Need To Know About Personalized Medicine
Health Outcomes Teams: Small Numbers = Big Impact
Can EUREQUO Improve The Quality Of Cataract And Refractive Surgery Again?
Science Fiction, Medical Writing And A Small Hobbit - What Do These Things Have In Common?
Are You Familiar With Alberta's Updated Price Policy?
UK Has A New Diabetes Drug On The Market
Contract Pharmacies - 4 Steps To Prepare For The 340B Program
Will Biogen Idec's Oral MS Drug Get Final Approval From NICE?
The New CMS Diagnosis Code - Will There Be A Smooth Transition?
Healthcare In High Definition: A Trend Report
Catamaran is excited to introduce its 2012 Informed Trends Portal, a dynamic way to view and understand key trends from Catamaran and related insights within the PBM industry. More here. (Source: catamaran).
Clinical Trials - How To Keep The Patient From Breaking Up With You
A successful clinical trial must maintain high levels of patient recruitment, adherence and retention, but this proves to be a significant challenge for researchers. Enter Behavioral Economics (BE), based on the idea that our behavior is mainly unconscious, irrational and socially driven. So how do we use BE in clinical trials? Read more here. (Source: tHEORetically Speaking, 9/06/13).
Germany - The "Wild Card" In Drug Pricing; How Will This Play Throughout Europe?
HealthEconomics.Com and J. Trotter Research & Consulting Launch Survey on Pharma Real-World Evidence
Biotechnology Monitor & Survey - Marketplace Policies, Practices, and Perspectives
So You've Written An Article - What's The Trick To Getting Published?
Take A Look At HealthEconomics.Com's New Connected Community Podcast Page.
The CONNECTED COMMUNITY™ Podcast Series explores relevant, controversial, or evolving issues in the field of health economics, market access, outcomes research, specialty pharmacy, HEOR medical writing, technology assessment, and more. Check out the CONNECTED COMMUNITY page here. If you would like to participate in a Podcast with Dr. Patti Peeples, contact us at firstname.lastname@example.org.
Have You Heard About HealthEconomics.Com's Webinar Service?
ISPOR Educational Video Series - Check Out The New Topics
The Future Of Specialty Drugs
Preventive Medicine - A Good Step For Reform?
JMCP Embraces Specialty Pharma, with a Journal Name Change
Medicare D: The Trojan Horse We Always Knew It Was
New Evidence Update From NICE
Run Run As Fast As You Can - You Can't Catch This HE Man!
LASER Announces Strategic Collaboration with H-Labs
LA-SER Analytica has announced a strategic collaboration with H-LABS Ltd in the area of scientific engagement and market access consulting. H-LABS was founded by Ed Godber to focus on the way in which engagement could increase the value of information submitted to decision-makers. Roman Casciano, the general manager of the Consulting & Analytics division of LASER Analytica commented: ‘’This strategic alliance is a tremendous opportunity for us to deepen our expertise and complement our market access consulting offer as our customers are increasingly pursuing scientific engagement to guide optimal development’’. Read more. (Source: LASER, 2/13/2014)
Orphan Drugs - Why Digital Should Be The Heart Of Your Marketing Strategy
There are many challenges to marketing orphan drugs. The need for awareness campaigns, the small number of patients who benefit from orphan drugs, and convincing payers of value together mean that one on one engagement is simply not a viable option. This is where the digital realm can be your friend. More information here. (Source: PMLiVE, 2/10/14).
Will German Epilepsy Patients Have Access To Fycompa Once Again?
After deciding to withdraw Fycompa from the market last year, rather than sell it at Germany's HTA agency approved price, Eisai's epilepsy drug, Fycompa could be re-entered onto the market as Germany takes another look at pricing. Read more here. (Source: PMLiVE, 2/11/14).
Mammograms - Improving Survival But Not Mortality - Do You Know The Difference?
Do you know the difference between survival rates and mortality rates? It's a very important difference, explained very well in this video, by Dr. Aaron Carroll of the University of Indiana. (Source: James Hamblin, The Atlantic, 2/12/14).
AMCP - Call For Monitors And Volunteers
Volunteering is a great way to give back to your association! The Academy of Managed Care Pharmacy is now accepting applications for Education Session Moderators, Booth Volunteers and Conference Buddies. More information here. (Source: AMCP, 2014).
What Defines Quality Health Care, And How Is That Related To Costs?
Join this discussion TODAY to discuss this critical issue with special guests in a live, G+ online event. TODAY at 2pm ET. Sign up here. (Source: Google+)
Nominate Yourself! Volunteer for a NASP Committee
The National Association of Specialty Pharmacy (NASP) is seeking professionals working in the specialty pharmacy industry who are interested in volunteering on a NASP committee. Self-nominations are encouraged. The NASP was founded in 2012 and represents specialty pharmacy professionals in all practice settings and highlights the unique value its members bring to patients and the healthcare system. More here. (NASP, 2/11/2014)
How Do You Put A Value On End Of Life Treatment?
OHE Explores Social Preferences And Burden Of Illness In Value-Based Assessments
Dr Donna Rowen from the University of Sheffield, presents her recent research on defining social preference. The research is intended to inform changes in 2014 in NICE's method of value assessment.
OHE's Koonal Shah recently presented his findings at the University of Oxford as part of the Health Economics Research Seminar Series at the University of Oxford. Koonal's presentation and Dr Rowen's presentation slides are available here. (Source: OHE, 2/11/14).
Company Says No To Downsizing & Rehiring - Seeks Out Training From Xcenda
In this case study, learn how Xcenda helped transform a sales team, unprepared to launch a new oncology product, by building new skill sets while keeping them in the field. Download case study here. (Source: Xcenda).
Nominations For The Robert F. Allen Symbol Of H.O.P.E. Award Are Underway
The Robert F. Allen Symbol of H.O.P.E. (Helping Other People Through Empowerment) Award honors individuals who have made outstanding contributions to promoting cultural diversity within health promotion or who have demonstrated significant achievement in serving the health promotion needs of underserved populations. Deadline for nominations is April 25, 2014. More information available here. (Source: American Journal of Health Promotion).
PROMs - Linked Data Required For Accurate Recruitment Rates
The routine use of patient reported outcome measures (PROMs) aims to compare providers as regards the clinical need of their patients and their outcome. Simple methods of estimating recruitment rates based on aggregated data may be inaccurate. Case study results here. (Source: 7th Space Interactive).
Call For Research Proposals: Affordable Priorities Towards Universal Health Coverage
The Middle East and North Africa Health Policy Forum (MENA HPF) is a non profit regional organization dedicated to the development of sustainable policies that improve health particularly for those who are most disadvantaged. The MENAHPF is pleased to invite submission of research proposals under the topic, Affordable Priorities Towards Universal Health Coverage. Submission deadline is April 10, 2014. More information available here. (Source: MENA HPF).
AMCP Members - Have You Cast Your Vote?
AMCP is holding elections for President Elect and three Board of Directors seats. All AMCP Active Members are encouraged to vote in this year's election. Ballots must be received no later than February 21, 2014. More information here. (Source: AMCP, 2014).
A New Way to Think About “Product Value”…Take a Lesson from Stanford MBA Students
A Group of Stanford MBA Students was given $5-10 and challenged to make as much money as they could with it in just one week. What was the point of this assignment? What would you do? Read more here. (Source: Quora)
Not to be missed! 10th Annual Specialty Pharmacy Summit & Expo
The latest version of the agenda for the 10th Annual Specialty Pharmacy Summit & Expo occurring on May 5-9, 2014 at the Wynn Hotel is now online! Hosted by Armada Health Care, this program is packed with the most current information on the specialty pharmacy industry and includes seminars and sessions by the country's foremost thought leaders and Pharma trade executives. View the agenda here. (Source: Armada, 2/10/14)
How Can Specialty Competencies Help Achieve ACO Goals?
Attend Part 2 of this free webinar series brought to you by Armada Health Care, Avalere Health and SPAARx.This webinar will discuss ways that specialty pharmacy providers can contribute to the achievement of accountable care goals. February 19, 2014 at 1pm. Register today. (Source: Avalere Health, 2/10/2014)
HEOR - 3 Steps To Using Social Media Effectively
Is social media important in your HEOR? What might the benefits be? Think past your limitations and read tHEORetically Speaking's The ABCs of HEOR Social Media. If you would like to be a guest blogger for tHEORetically Speaking, please contact HealthEconomics.Com. (Source: theoretically Speaking).
What Did You Think Of The ISPOR 2012 Budget Impact Analysis? Read This Review
Should off-label use be included in a BIA? What did you think of the recommended reporting format? Do BIAs hold any relevance for Decision Making? Read more here. (Source: Elsevier, Value In Health, 2014).
Improving The Usefulness Of Budget Impact Analyses
The report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force updates the previous guidance published in 2007. With these caveats in mind, this review believes that following the guidance provided by the task force will meaningfully improve the validity, transparency, and flexibility of BIAs provided to payers and other users in an increasing variety of different settings. More here. (Source: Elsevier, Value In Health, 2014).
ISPOR Task Force Report - Budget Impact Analysis - Principles Of Good Practice
Budget impact analyses (BIAs) are an essential part of a comprehensive economic assessment of a health care intervention and are increasingly required by reimbursement authorities as part of a listing or reimbursement submission. Objectives: The objective of this report was to present updated guidance on methods for those undertaking such analyses or for those reviewing the results of such analyses. Read more. (Source: Elsevier, Value In Health, 2014).
How Much Are Health Outcomes Affected By Hospital Resources?
This report contains information collected by the NHS in England. Since 2009, they have collected PRO data for four elective procedures. Their research produces a number of important insights about the best approaches for using PRO data, the determinants of health outcomes for individual patients, and whether and what variations in outcomes can (and cannot) be explained by differences across hospitals in resource use. Read more here. (Source: OHE, 2-06-14).
Will Specialty & Community Hospitals Survive Reform?
In an unexpected consequence of reform, insurers are dropping specialty and community hospitals from provider networks! The federal government, however, may not tolerate excessive network cuts and are proposing new policies. More information available here. (Source: Jane Antonio, FierceHealthPayer, 2/07/14).
5 Reasons Why You Should Attend This Workshop
The primary focus of this workshop on cognitive interviewing, is on how to effectively develop verbal probes and conduct verbal probing for evaluating measurement equivalence across data collection modes. Read here for 5 reasons why You should attend Cognitive Interviewing For Evaluating Measurement Equivalence Of Electronically Migrated PRO Instruments. (Source: DHP Research, thepatientoutcomesblog, 2/04/14).
What If Shopping For Healthcare Were More Like Shopping For A Car?
It's hard to believe in this day in age, when we are able to get on the internet and research price, safety, and pretty much anything we want to know about any purchase we make, that the same is not true with healthcare. How are we to make decisions with such little transparency? Read more Pricing Cars Like Healthcare, by Debra Gordon. (Source: Debra Gordon, tHEORetically Speaking).
Can Payers Close The Gap Between Medical & Pharmacy Benefits?
Data from Zitter Health Insights’ Managed Care Biologics and Injectables Index shows that a consistent, overwhelming majority of payers believes that the potential benefits of integrating medical and pharmacy management outweigh the costs and challenges, but find their organizations' management of this process to be sub-par. Read more. (Source: Cassandra Habura, zitter Health Insights, 1/28/14).
Saama's New Business Consulting Practice - Helping You Harness Big Data
Saama recently announced their new Business Consulting Practice for Analytics and Big Data Initiatives, which aims to democratize the access to data and the analytical processes that can enable action. Read more here. (Source: saama, 2014).
Big Data's Impact On Innovation Workshop - Only A Few Days Left To Register!
Leveraging Big Data II: What Does It Mean For Improving Product Development And Health Care. This conference, sponsored by the University of Maryland Center of Excellence in Regulatory Science and Innovation and the FDA, in collaboration with the National Pharmaceutical Council, will take place on February 11, 2014. It will bring together researchers from the FDA and other government agencies, industry, and academia to continue the M-CERSI dialogue and scientific exchange on big data and its role(s) in and impact on medical product development. (Source: University of Maryland School of Pharmacy, 2014).
Multiple Sclerosis Remains A Hot Topic Among Manufacturers And Payers
Multiple sclerosis remains one of the most frequently discussed therapeutic areas between pharmaceutical manufacturers and payers, driven in large part by visits from oral MS agent manufacturers. Read more here. (Source: Tracy McCarrick, zitter Health Insights, 1/17/14).
University Of Sheffield Seeks Dissertation Hosts
The students will be ideally suited to undertake a cost-effectiveness analysis, or related quantitative research. They will have developed models using TreeAge, Excel and Simul8. They will also have taken modules in Medical Statistics, Operational Research Techniques and Health Economics. Students undertake the placement from July to September inclusive (full time). If you are potentially interested in hosting a student, or would like to find out more information, please email Jon Tosh. Deadline for proposed placements is March 14th.(Source: University of Sheffield)
What Do You Think About CVS' Stand Against Tobacco?
Effective October 1, 2014, CVS Caremark will discontinue the sale of cigarettes and tobacco products at more than 7600 locations. They will also be launching a program to help members quit smoking! Read more here. (Source: First Report Managed Care, 2/05/14).
Is The Diabetes Health Profile Going Paperless?
Potential advantages of moving from paper to an eDHP: Accelerated treatment and intervention evaluation, Enhanced treatment adherence, New avenues for predictive outcomes and tailored therapeutics, Improved understanding of patient populations and compare subgroups. More information available here. (Source: DHP Research thepatientoutcomesblog, 2/04/14).
Specialty Pharmacies: Going Smart Instead Of Going Big
In this Connected Community podcast conversation, Richard Carlson from Blue Fin Group, and Dr Patti Peeples, CEO and Founder of HealthEconomics.Com discuss how Pharmaceutical Manufacturers and Specialty Pharmacies are 'going smart' instead of 'going big' when thinking about data, analytics and contractual requirements. More information here. (Source: Richard Carlson, Finsights, 02/04/14).
Submission Request: Health Economist Influence On Policy In US vs Other Developed Countries
Applied Health Economics and Health Policy is planning a themed issue on the question of whether health economist in the US have a different influence on policy than health economists in other developed countries. Submission DEADLINE is June 30, 2014. For suggested topics and other information on submissions, check here. (Source: Adis, 2014)
ACOs - Time For A Come Back?
Experts Plan To See More Plan-Sponsored ACOs On The Insurance Exchanges, some are even projecting that up to two-thirds of the country could be covered by ACOs in the next five years. All agree the success of ACOs will depend on their ability to bend the cost curve and not just improve quality. Read more here. (Source: Neal Learner, AISHealth, 1/27/14).
There's A New Journal In Town - The American Journal Of Health Economics
The inaugural issue of the American Journal of Health Economics, the official journal of the American Society Of Health Economists, will appear in the first quarter of 2015 and submissions are being accepted NOW! For more information on journal content, submissions, check here. (Source: MIT Press Journals)
Have Payers Given Up On The Digital Consumer?
While payers have drastically pulled back on App launch experimentation, they seem to be focusing efforts in more precise areas such as: payer-owned consumer data aggregation platforms, biometric tracking initiatives, the next generation of social media platforms and more. Full Article available here. (Source: Brian Dolan, mobihealthnews, 1/27/14).
80 Economic Evaluations Have Been Added To NHSEED
University of York - Centre For Reviews And Dissemination. More information here. (Source: University of York, 2014).
100 Systematic Reviews Have Been Added To DARE
University Of York - Centre For Reviews And Dissemination. More information here. Source: University of York, 2014).
Call For Papers - Hematology/Oncology
American Health & Drug Benefits readers are invited to submit manuscripts for the May 2014 issue themed issue, Hematology/Oncology; including original research, cost-effective analyses, evidence-based comprehensive reviews, case studies, and industry surveys/trends. Submission Deadline is March 17, 2014. More information available here. (Source: American Health & Drug Benefits, Nov/Dec 2013).
Journal of Managed Care Pharmacy - Expanding Its Reach to Specialty Pharma and More!
The Academy of Managed Care Pharmacy recently announced the first major expansion of the Journal of Managed Care Pharmacy. The expansion targets specialty pharma, ACOs, medical directors, and more. More information available here. (Source: The Sacramento Bee, 02/03/14).
Big Government = Big Data: How Much Information Is The FDA Really Collecting?
FDA's "Mini-Sentinel" project recently released a report on the massive amounts of personally identifiable health data it has been collecting. As of 2012, the database contained data on more than half the United States. How secure is this data? Read more here. (Source: Pharma Marketing Blog, 02/01/14).
PMPRB Published Final 2013 Price-Adjustment Factors
The actual rate of consumer price index (CPI) inflation for 2013 was 0.9%. The final year-over-year price increase cap for 2013 is 1.4% (= 1.5 x 0.9%). More details available here. (Source: PMPRB, January 2014).
NASP Specialty Pharmacy EXPO Opens for Registration
The National Association of Specialty Pharmacy (NASP) has opened registration to attendees and sponsors for its Specialty Pharmacy EXPO, scheduled for March 31 - April 4 at the University of South Florida's Center for Advanced Medical Learning and Simulation (CAMLS), a state-of-the-art facility in downtown Tampa. The EXPO brings together leaders and decision makers from the industry to discuss the latest issues and trends. It offers valuable networking opportunities with colleagues and exhibitors as well as 90 hours of accredited, specialty pharmacy education. Registration for the event is available here. (Source: NASP, 1/30/2014)
From Dolls To Adults - This HE Artist Has You Covered!
Meet Luminita Vopsaroiu, HE Artist of the Week! During her 18 years as a medical statistician, Luminita continued her life long passion as a textile artist. What was once only a hobby soon became an additional source of income as her client base began to grow! Read more about Luminita here. If you or someone you know would like to be featured in the HE Artist section, please contact HealthEconomics.com. We'd love to share your story!
ISPOR Global Health Care Systems Road Map
An overview of country-specific health care delivery systems focusing on reimbursement and pricing approval processes for pharmaceuticals, medical devices and diagnostics, which includes validated decision models that define decision makers and the decision-making processes for coverage, reimbursement, and pricing. More information here. (Source: ISPOR).
ISPOR - Pharmacoeconomic Guidelines From Around The World
Pharmacoeconomic (PE) guidelines can be used as a standard for preparation of studies to be included in application for reimbursement, a guide for designing and conducting a study, or a template for evaluating the economic study reports. More information available here. (Source: ISPOR)
The Negative Side Of An Inappropriately Positive Title
This article contains correspondence to the editor of The New England Journal of Medicine regarding an article by Von Hoff et al., Oct 31 issue, entitled "Increased Survival in Pancreatic Cancer With nab-Paclitaxel Plus Gemcitabine." The title was described as inappropriately rosy, citing modest benefits and substantial toxic effects. Read more here. (The New England Journal of Medicine, 1/30/14).
Who Will Provide Funding For PCORI's Continued Growth?
PCORI May Look To The NIH, The FDA Or To Health Industry Partners.‘I sure hope the NIH finds ways to use the network,’ said [PCORI Executive Director Joe Selby], who also noted that [NIH Director Francis Collins] is providing input into the development of the network...Collins has been a cheerleader of the new efforts. ‘NIH is thrilled that these organizations have come together and agreed to create a single, overarching network that will be seamlessly integrated using electronic databases,’ he wrote… Paid Subscription Required. (Source: Rebecca Adams, CQ HealthBeat, 1/29/14).
Has Congress Stopped The Push To Repeal PCORI?
During the run-up to the passing of the Affordable Care Act, the Patient-Centered Outcomes Research Institute was the target of much Republican criticism. But based on her interactions with congressional members, Project HOPE’s Gail Wilensky says there’s no desire now on Capitol Hill to end the institute’s activities. Purchase Required to read more. (Source: Gregory Twachtman, The Pink Sheet Daily, 1/29/14).
Walgreens Brings Big Data Analytics To Healthcare Clinics
The convergence of Inovalon’s data-driven patient assessment tool, Electronic Patient Assessment Solution Suite (ePASS®), and Healthcare Clinic at select Walgreens creates a unique offering within the health plan and retail clinic industry. By integrating data analytics, they expect to help improve patient care and outcomes. More here. (Source: Business Wire, 1/30/14).
AMCP Warns: Proposed Part D Changes Could Undermine Program
AMCP urges against changes to preferred networks, mail-order pharmacy and MTM in Part D- saying these changes would increase costs to the program and beneficiaries as well as roll back any recent progress. Read more here. (Source: Digital Journal, 1/30/14).
For Clever Ways to Present Health Outcomes Data, Look to the….State of South Carolina!
Who would have thought that a state government group would deduce one of the most clever ways to present healthcare data, for easy interpretation by consumers (and healthcare professionals). Check this out by the state of SC on diabetes, ESRD, and Obesity. Read more. (Source: Anthony Brino, GovernmentHealthIT, 1/30/14).
Is Bigger Always Better? Big Data vs. Smart Data
This article does a good job and breaking down the differences between big data and smart data and discusses the benefits of using smart data in marketing pharmaceuticals. Read more here. (Source: Joe G, CBI, 1/24/14).
Upcoming Webinar On Clinical Trial Design And Development Strategy
Webinar: Transforming Clinical Development Strategy And Performance With Real-World Data
Context Matters CEO, Yin Ho, will be on a panel for the upcoming free webinar, Transforming Clinical Development Strategy and Performance With Real-World Data. The webinar is sponsored by Oracle Health Sciences and Pharmaceutical Executive. More information here. (Source: Context Matters, 2014).
More Regulation or Better Regulation?
Professor Alan Maynard, University of York, delivered the 20th OHE Annual Lecture, Contracting For Quality In The NHS. His thoughts on fixing patient care deficiencies in the NHS differ than those recommendations in the Francis Report. He suggest that better regulation is needed, not necessarily more regulation. Read more here. (Source: OHE, 1/28/14).
DIA & PCORI Collaborate To Bring You This Complimentary Webinar
Webinar: February 5, 11am-12:30pm
Patient-Centeredness and Engagement in Clinical Research: Opportunities for Industry, explores how PCORI and other stakeholders are advancing patient-centeredness and engagement in research, what we know so far about the impact of this trend, what we hope to learn in the future, and the implications for industry. (DIA, 2014).
Are Hospitals Profiting From Patient Complications?
This blog, Hospital Profits Higher When Surgical Patients Develop Complications was written by Debra Gordon in response to a study published in the Journal of the American Medical Association, April 17, 2013. (Source: Debra Gordon, tHEORetically Speaking, 2013).
tHEORetically Speaking Invites You To Share Your Thoughts
The Official Blog Of HealthEconomics.com, tHEORetically Speaking, invites anyone in the field of healthcare value and market access to share their insights, predictions, and general thoughts on the state of global health economics. If you’d like to share with our audience, please contact us! Good jokes are always welcome too.
Top Five Metrics Evaluated To Measure ACO Success
HINs ACO Survey & Chart Of The Week:
HIN's ACO survey captured how 138 healthcare organizations are participating in ACOs, including who administers the ACO, which providers participate in the ACO, the top components of an ACO, and much more. Find out what the top five metrics evaluated to measure ACO success are here. (Source: HIN, 1/29/14).
Snakebite: At Some Point, Healthcare Costs Need to Be Defendable
Snakebite Victim Charged $89,000 For 18 Hour Hospital Stay! The hospital charged $81,000 for anti-venom medication which can be found online for $750? Don't worry- I'm sure the hospitals has a good explanation for this….Read more here. (Source: Dylan Stableford, YAHOOnews, 1/28/14).
Satisfaction Goes Social
What happens when patient [dis]satisfaction goes social? Are payers, providers and third party stakeholders missing an opportunity? Read "Satisfaction Goes Social" by Laurie Gelb and join the conversation. (Source: tHEORetically Speaking, 3/15/13).
What Are The Most Important Topics To Watch In Health Policy 2014?
Three experts, David Howard, PhD, of Emory University's Rollins School of Public Health, Michael Morrisey, director of the University of Alabama at Birmingham's Lister Hill Center for Health Policy, and Joe Antos, of the conservative American Enterprise Institute; focus on continuing enrollment and implementation of the Affordable Care Act and trends in healthcare spending. Check out this video - Hot Topics 2014: Health Policy! (Source: medpage Today, 1/28/14).
Is The ACA Trying To Cover Too Much?
The Authors of this article do not think the ACA is on track to solve any of the problems it was intended to. They have an idea on how to achieve universal health coverage at HALF the cost, while solving those problems. They suggest that the ACA is trying to cover too much and should only protect against serious or catastrophic financial loss. What do you think about their plan? Read more here. (Source: Kip Hagopian & Dana Goldman, Forbes, 1/10/14).
Are Public Healthcare Information Exchanges In Jeopardy?
With doctors not trusting the records or seeing a meaningful connectivity, grant money running out and provider networks and hospitals considering private HIEs, it seems inevitable. Public HIEs need more effective processes, revenue streams and business models if they want to stay in business. Read more here. (Source: Susan Hall, FierceHealthIT, 1/28/14).
Is Hepatitis C Cure Worth $1000/day?
Gilead's new 12 week treatment cost $84,000! Such stratospheric prices for this new drug and many other breakthrough treatments has caused insurers to look at alternatives to covering high-priced hepatitis, diabetes and other treatments. What does this mean for patients? More information here. (Source: Drew Armstrong, Bloomberg Personal Finance, 1/27/14).
PatientsLikeMe CEO - Keynote Speaker For DIA 2014 50th Annual Meeting
Jamie Heywood is one of the foremost practitioners using technology to transform the future of health care. He is the founder of PatientsLikeMe, a personalized research and peer care platform that allows patients to share in-depth information on treatments, symptoms and outcomes. He is also the founder of ALS TDI, the world’s first nonprofit biotechnology company. He will be presenting during the opening plenary on Monday June 16 for DIA 2014 50th Annual Meeting. (Source: DIA, 2014).
Is Bigger Always Better?
Data, data, data. Blogger Richard Carlson discusses how Manufacturers are often "buried in specialty data complexity and how the incompleteness and inaccuracies overwhelm and make the data difficult to use. The problem is that many manufacturers have gone “Big” with their specialty pharmacy data and have not gone “Smart” or “Right Size"." Are you asking the right questions about your data? Read more. (Source: Finsights, 5/20/13)
Need a Comprehensive Review of the Specialty Pharmacy Model?
Then this seminar is for you. This two-part seminar offers an in-depth analysis of the specialty pharmacy industry, including: historical and future market analysis, the channel structure and the provider service model. It concludes with an interactive Q&A session with an expert pharmacy panel on the opportunities in this marketplace. This seminar is offered at the 10th Annual Specialty Pharmacy Summit & Expo. Learn more. (Source: Armada, Jan. 2014)
BAYER - Making Waves With Pricing And Charges of Racism
India has been following its own patent laws in an attempt to give its people access to a new cancer-fighting drug, Nexavar. Bayer is the manufacturer of Nexavar which cost $69,000 annually compared to the Indian pharmaceutical company Natco Pharma Ltd who was able to offer it for just $177!! The response from Bayer's CEo will shock you! Read about it here. (Source: Adam Peck, ThinkProgress, 1/26/13)
Value-Based Assessment In The UK - How Will It Be Implemented?
In this presentation, Adrian Towse explains, VBA replaces ‘value-based pricing’, which as originally proposed in the UK was intended to achieve several objectives including broadening the definition of value. Adrian’s presentation reviews important issues in defining value, demonstrates how past policies aimed at value have affected the availability of some medicines, and suggests ways forward under the modified, VBA approach. More here. (Source: OHE, 1/23/14).
Is PCORI Falling Short Of Its Potential?
Critics claim the health law did nothing to control costs, but has the potential to bend the cost curve over the long term. Can the institute carry out a bold enough research agenda to live up to that potential? Paid Subscription Required. (Source: Bronwyn Mixter, Bloomberg BNA, January 2014).
Does ISPOR See The Real Importance Of Innovative Technologies?
This discussion regarding newer technologies, and more specifically Symbolic Math tools, continued between Anderew Briggs and the author, Jacob Barhak, via email. Now made public, interested parties are welcome to view a summarized transcript here. (Source: Jacob Barhak, Sim, 1/13/14).
Ben Goldacre Makes The Case For Greater Transparency In Clinical Trials
In this podcast, Pharma IQ discusses the issue of clinical trial transparency with Dr. Goldacre, with a focus on how it will affect industry and why pharma companies have taken differing strategies in response to the campaign. Listen to podcast here. (Source: Pharma iQ, 1/21/14).
Pharmaceutical Companies - How Will Brazil's Drug Price Index Affect You?
The Brazilian government did not publish the drug pricing formula used in September as it normally does. Where does this leave pharmaceutical companies trying to prepare for 2014? Read more here. (Source: Katie Bell, FirstWord Pharma, 1/20/14).
3rd Annual Conference On Healthcare Markets - Call For Papers
Northwestern University's Kellogg School of Management will be hosting the 3rd Annual Conference on Healthcare Markets on May 16, 2014. For a list of possible topic areas and more information of manuscript submission click here. (Source: Northwestern University, January, 2014).
Who's Ready To Samba? Check Out This Week's HE Artist!
Meet LeeAnn Braun, Associate Director, Market Access and Outcomes Strategy at RTI-HS and Competitive International Latin Dancer!! Just how does one enter the world of competitive dancing? Find out more about this HE Artist here. If you or someone you know would like to be a featured HE Artist, please contact Healtheconomics.com.
Special Issue Of Risk - Call For Papers
The intent of this special issue of Risks, Risk And The Economics Of Health, is to offer a forum for the examination of the impact of risk on the behavior of consumers, providers and insurers, and ultimately the implications for the efficiency of the health care system. We are calling for high quality papers discussing these issues, both from theoretical and empirical perspectives. DEADLINE for paper submission is May 15, 2014. More information available here. (Source: risks, 2014).
Young Adults in Obamacare - What Their Enrollment Means For HEOR Researchers And Claims Analysis
Almost 2.2 million people have enrolled in health coverage through the federal and state exchange marketplaces. 24% of these new enrollees are classified as the young invincibles, ages 18-34yrs. Is this enough for success of the program? Read more here. (Source: Julia Brown, Managed Healthcare Executive, 1/13/14).
UK - How Much Does Your Location Affect Your Access To Medicine?
This report was developed by a joint working group involving the Department of Health (DH), NICE, HSCIC and the pharmaceutical industry to assess how well patients are able to access the medicines approved for use by NICE. Read more. (Source: FirstWord Pharma, 1/22/14).
What Are The Top Journals For Today's Health Economist?
The intention of this paper is to create a list that exposes possible research outlets for health economists and to help demystify the relative rankings of such outlets using established objective measures. Download here. (Source: Social Science Research Network, 5/4/13).
Dublin Congress Extends Deadlines!
Due to high demand on their system, Dublin Congress has decided to extend deadlines for organized session/individual abstract submissions and the early bird rate for congress registration.
New Deadlines are:
Organized session and individual abstract submission deadline has been extended to Tuesday January 28, 2014 at 10:00pm EST.
Congress early bird registration has been extended to Wednesday January 29, 2014 at 10:00pm EST
Any questions or concerns please contact:
Paula Richardson, Membership Director, iHEA
Price Gouging & Racketeering - Top 10 Offending Hospitals
National Nurses United's (NNU) research arm, the Institute for Health and Socio-Economic Policy, conducted research on hospital pricing practices. It found evidence of what the group calls "price gouging" and "racketeering." Here are the top 10 hospitals with inflated prices. (Source: Managed Healthcare Executive, 1/06/14).
9 Factors That Drive Healthcare Cost
From the Miller Center, University of Virginia, 9 Factors That Drive Healthcare Cost. More here. (Source: Managed Healthcare Executive, 1/09/14).
Pharma Pricing Breaking News
Pharmaceutical pricing strategies go well beyond what the market will bear, but what really works? Breaking news stories for the pharmaceutical industry in the pricing, market access, and health outcomes arena in HealthEconomics.Com, January 13th, Newsletter. Read Here. (Source: PRWeb, 1/17/14).
Reflections On Operationalising Value Based Assessment
A Slideshow From The Office Of Health Economics. Value-based pricing, as originally proposed in the UK, was intended to achieve several objectives, including broadening the definition of value. This presentation reviews important issues in defining value, demonstrates how past policy aimed at value has affected the availability of some medicines, and suggests ways forward under the revised, value-based assessment approach. See more here. (Source: OHE, 1/13/14).
Need A Guide to Value-Based Reimbursement?
The Guide to Value-Based Reimbursement: Profiting from Payment Bundling, PHO Shared Savings, and Pay for Performance explores emerging models of episode-based payments, physician-hospital organizations and physician bonus structures. Purchase your copy here. (Source: HIN, 2013).
Pharma Firms- Pick Your Penalty!
Faced with a very limited staff, the National Pharmaceutical Pricing Authority (NPPA) is finding itself unable to calculate the companies' penalty and has instead left that up to the individual companies. So... how do you think this will turn out? Read more here. (Source: Business Standard, 1/20/14).
Achieving Quality in ACOs: Are They Ready to Maximize the Value of Pharmaceuticals in Patient Care?
NPC Webinar NOW AVAILABLE ONLINE! Did you miss this week’s webinar from the National Pharmaceutical Council, on accountable care organizations (ACOs), that explored how ready ACOs are to implement the structures and processes needed to maximize the value of pharmaceuticals? Speakers outlined the activities that ACOs are doing well, and shared insights on where there is room for improvement. Available here. (Source: NPC, January 2014).
Webinar On The Health Insurance Exchanges Tomorrow!! January 23!
This Webinar from Zitter Health Insights will cover topics such as: Anticipated enrollment in the exchanges at the disease state level, Factors that consumers consider when enrolling in an exchange plan, Demographic profiles of uninsured consumers, Maximum monthly premium & out of pocket cost these consumers are willing to pay and more. Please contact Michala to RSVP, and join meeting here. (Source: Zitter Health, 1/22/14).
What's So Special About Specialists' Care?
This article takes a look at specialists' care as compared to physicians. They're making more money that's for sure, but why? Do the procedures take longer? Do they require more intensive training? What percent of American health care expenses come from Specialist care? The answers may surprise you! Read more. (Source: The New York Times).
How Do You Put A Value On Health At The End Of Life?
A Slideshow from the Office of Health Economics, Valuing Health at the End of Life. More here. (Source: OHE, 1/21/14).
Take A Look at The State Of American Health Care From A Behavioral Economics Perspective
Featured speaker Dr. Douglas Hough has written a new book which looks at the state of American health care through the lens of behavioral economics. With it, he hopes to encourage patients, physicians and policy makers to make better choices for the nation's health and well-being. Podcast available here. (Source: World Congress, 2014).
How Much Privacy Do You Give Up With Patients Like Me?
What Is The Real Cost Of Medication Noncompliance?
Dr. Hayden Bosworth addresses the cost of medication noncompliance and why different groups in the healthcare sector need to come together in order for solutions to work. Podcast available here. (Source: World Congress, 2014).
Pharma & Tobacco Companies - Can We Trust Either?
How much honesty can we expect from industry-backed research? According to this author- not very much. Which is why he has called for medical journals to ban the publication of research funded by pharma companies. Read more here. (Source: PMLiVE, 1/17/14).
Interview With Beate Wieseler, IQWIG
Germany has emerged as one of Europe's most financially stable counties. One reason for this is the government's effort to keep costs low. The following article interviews Dr. Beate Wieseler on many aspects of Germany's spending in the area of healthcare. Read more here. (Source: PMLiVE, 1/8/14).
Call For Papers: Deadline Extension
This themed issue of Applied Health Economics and Health Policy is set to explore the question of whether health economist in the US have a different influence on policy than health economists in other developed countries. For a list of specific questions that could be addressed by articles in this issue, or information on submissions, click here. (Source: Adis, 2014).
Now Available - Published Thought Piece On The Value Of Surrogate Endpoints In The EU3
CBPartners has evaluated several recent launches across specialty and oncology therapeutic areas to understand how G-BA / IQWiG, NICE, and the HAS view the use of surrogate endpoints in making a value-based argument, in order to better understand and mitigate the barriers likely to be encountered by manufacturers throughout the pricing and reimbursement process. Please contact Rachel Beckerman at CBPartners for a copy. (Source: Linkedin, Jan, 2014).
Looking To Amp Up Your New Product Development?
Moving from “Cost-Based, Product Driven” to “Value-Based, Customer Driven.” Using the value-based, customer driven process ensures that from the moment the new product is released, customers will already be aware of how it will add value in their business processes. Read more here. (Source: PROS, 1/14/14).
Despite Price Caps, Indian Pharmaceutical Sales Recover
After dipping this past fall after the implementation of the New Pharma Pricing Policy (NPPP), the overall volume growth has started to rebound. IPCA Laboratories, Glenmark Pharma and Sun Pharma lead December 2013 domestic growth. Read more. (Source: Business Standard, 1/19/14).
Wondering How To Prepare For A Virtual Career Fair?
On January 23, 2014, between 9am-1pm, HealthEconomics.Com is hosting the first ever virtual Career Fair focused on HEOR, PRMA, and Data Analytics in HE-Xpo. What can employers and job seekers do to prepare for this? This blog contains important information you need to know, including an interview with Klein Hersh Executive Recruiters. Read more here. (Source: tHEORetically Speaking, 1/16/14).
India maintains price controls on time-release drugs
The National Pharma Pricing Authority (NPPA) had originally included this set of drugs while fixing price caps last year, but the ministry recently told the authority that time-release set of drugs should be excluded. What happened next? Read here to find out. (Source: The Economic Times, 1/15/14).
Can German Physicians Save The Drug-Assessment Program?
The new administration says it will scrap the system, but many argue that this step will make it more difficult for doctors and patients to access independent information and fear the return of a time when drug makers were able to set their prices freely in Germany. Read more here. (Source: PharmaTimes, 1/15/14).
ABPI Code Updates Are In Effect - What Does This Mean For Pharma?
The latest update to the Association of the British Pharmaceutical Industry's (ABPI) Code of Practice came into effect at the beginning of the year. For information on grace period, read full article here. Details of the change along with a PowerPoint presentation and a copy of the 2014 Code are available on the ABPI's website. (Source: PMLiVE, 1/16/14).
NASP Practice Parameters Project – Call For Volunteers Due Monday, January 27
NASP Members, Your Participation In This Project Is Key To Its Success! NASP is recruiting volunteers with knowledge and experience in the specific therapeutic categories to serve on Advisory Groups that will help spearhead this project. Volunteers are still needed in the following, initial therapeutic categories: Diabets, Hep C, HIV, Oncology-Breast, Oncology-Multiple Myeloma, Oncology-NHL. More information available here. (Source: NASP, 2014).
A Look At The Ethical Consequences of Using The New Decision-Making Process
Ethical medical decision making as an integral part of medical practice is based on four principles: Do well, Do not hurt or damage, Respect patient's autonomy, and Behave justly. The ethical consequences of these concepts in the decision-making process for pharmaceuticals is explored in this article by applying the principles of medical ethics to the current health care policy for pharmaceuticals. Read more. (Source: ISPOR Connections, Nov/Dec 2013).
AMCP Seeking Business Plan Writers
AMCP is seeking individuals who have experience in writing business plans for products for the managed care pharmacy and healthcare marketplace. Interested parties must have experience writing detailed business plans for multiple clients and have plans that have been successfully implemented in order to be considered to receive the RFP. If you meet these requirements and would be interested in being considered to receive an RFP, please email Betty Whitaker, Director Member Services and Marketing at AMCP, your name and a brief overview of your experience.
Who Are The Leading Influencers In European Evidence Development?
The top influencers were chosen based on their experience, career achievements and contributions to evidence development. Dowload ebook: Top 10 Influencers in European Evidence Development here. (Source: totalbiopharma, 2014).
BioPharma Asia Convention 2013 - Which Presentations Were Your Favorites?
Many presentations delivered at the BioPharma Asia Convention 2013 were released last year, sparking off numerous conversations, discussions and debates. Find out what the top 20 presentations were by downloading this ebook. (Source: totalbiopharma, January 2014).
Will Older Patients Lose Out With Proposed Changes To NICE?
Recent Proposed Changes to the way in which treatments are evaluated for the NHS, some say, could lead to restricted access to certain drugs-particularly for older patients. What does NICE have to say about this? Read here to find out. (Source: Optometry Today, 1/16/14).
Understanding The New Health Economics
Published in October 2013, this video is still valid in explaining current health economics issues, ACA and care integration. Watch this YouTube video: Understanding the New Health Economics 2013. (Source: ToshibaMedical, 10/4/14).
How Can You Use Analytics To Streamline Care And Maximize Revenue?
In this eBook, readers will learn how to use data analytics tools to gain actionable insights from clinical, financial and administrative data, which can help hospitals target services and personalize care. Download your copy of Data Analytics: Actionable Information To Improve Healthcare, today! (Source: FierceHealthIT, 2014).
FDA Collaboration To Create Big Data Paradigm
Global Record Systems & FDA To Create Big Data Paradigm For Collection Of Patient Safety and Outcomes Information
This initiative is designed to generate disruptive solutions to challenges related to patient safety, clinical outcomes, and medication adherence. Global Record Systems is providing a cloud-based digital health platform to collect patient-centered data on a near real-time basis. The FDA will provide GRS with clinical research questions to inform the data collection and analysis. Read more. (Source: PRWeb, 1/14/14).
Why Do We Need Health Economics And Outcomes Research?
This animated video, by Health Outcomes Strategies, uses a more familiar example of using comparisons and looking at alternative options, by looking at how we make a decision on how to travel, and then showing a similar process used in healthcare. Click here to watch. (Source: HealthOutcomesStrats, 3/26/13).
What Scientific Ideas Do You Think Are Ready For Retirement?
Here is a new compendium Of essays By 166 (And Counting) Deep Thinkers, Scientists and Writers. Topics include: free will, evidence-based medicine, human nature and more. No matter who you are, you are bound to find something that will drive you crazy. The whole thing runs more than 120,000 words. You can dip into it anywhere and be maddened, confused or stirred. If there is an overall point, it is that there is no such thing as a stupid question. Read more. (Source: The New York Times, 1/14/14).
What Is The One Thing Politicians Could Do To Improve Healthcare In The US?
And How Many Of You Will Share Your Thoughts With Your Senator/Representative?
If you had to write a one page memo to a Senator/Representative detailing the one thing they could do to improve healthcare in the U.S., what would it be? This authors answer to that very question - comparative effectiveness research. Read his memo here. (Source: John Mandrola, 1/13/14).
Social Media & Pharma - What's OK With The FDA?
The FDA recently released draft social media guidance, giving pharma some substantial direction on its use of digital media. Read more here. (Source: Dominic Tyer, PMLiVE, 1/14/14).
FDA Reaching Milestones With COA Developers
Evidera recently announced the release of FDA Draft Guidance on the use of the Qualification of Exacerbations of Chronic Pulmonary Disease Tool (EXACT), to measure symptoms of COPD Exacerbations. Read more. (Source: PR Newswire, 1/14/14).
Results Are In - How Does Your Salary Compare?
Earlier this year, The Clinical Professionals Group surveyed professionals from Europe who work within the pharmaceutical industry, across a variety of pharmaceutical sectors, to identify the average salaries for each job level and how satisfied professionals were with their current salary package. More information available here. (Source: Elysia Robinson, Clinical Professionals, 1/7/14).
A Look At Heroism And Terminal Illness
This article takes us into the life of Lisa Bonchek Adams who is in the midst of a very public fight against cancer-and she is NOT giving up. She has been blogging about her battle for 7 years and fighting this disease every step of the way. We've all heard the stories of these warriors, strong and brave, but what about the people that have chosen to accept their disease as an inevitable fate with grace and courage? Read more here. (Source: Ben Keller, The New York Times, 1/12/14).
Avella Offers Guide to Selecting the Appropriate Specialty Pharmacy for Patients with Hepatitis C
Avella Specialty Pharmacy has introduced Guide to Selecting the Appropriate Specialty Pharmacy For Patients with Hepatitis C. This whitepaper highlights important factors to consider when choosing a specialty pharmacy including the ability to provide comprehensive, quality clinical services to patients and to support the needs of the patients with hepatitis C. View the white paper here. (Source: Avella, 1/9/2014)
6 Things Docs Should Know About The ACA
MedPage Today asked for Expert Opinions On What Doctors Need To Know As This Law Goes Into Effect. It's not only the increased number of people with health insurance that doctors should be concerned with: high deductibles, grace periods, narrow provider networks, and changing health plans - look over this list of ACA-related issues. Full article available here. (Source: David Pittman, MedPage Today, 1/2/2014).
Singapore, Schizophrenia, And Sea Bass With Sizzled Ginger
What's hot at CEMPH? - aside from the recipe for Sea Bass with Sizzled Ginger, Chillies, & Spring Onions (sounds absolutely phenomenal-but they make you wait till the last page for it!). Check out the Winter 2013 issue of the INSIDER, from the Centre for the Economics of Mental and Physical Health (CEMPH), King's College London. (Source: CEMPH, December 2013).
Career Fair Goes Virtual - Why You Want To Be Apart Of This!
The HEOR Career Fair in HE-Xpo® - will run from 9am-1pm ET on January 23, 2014. Exhibitors, job seekers, and employers can interact in a virtual, web-based environment, to showcase jobs, exchange resumes, conduct interviews through real-time chat, and learn effective interview techniques. Online presentations, webinars, and podcasts will be accessible, covering career options in HEOR and the pharmaceutical industry, as well as job search tips and opportunities for career growth. Register now! (Source: PRWeb, 12/18/14).
For information about participating in HE-Xpo® as an exhibitor and sponsor, contact Leslie Fine, HE-Xpo® Marketing Manager.
What Does ABPI Have To Say About NICE Proposals?
Paul Catchpole, Value and Access Director at the ABPI, welcomes the concept put forth in these new NICE proposals on value based assessment criteria, but says it's too early to understand the full impact they will have on future medicines access. Read more here. (Source: FirstWord Pharma, 1/10/14).
AMCP Members - What Do You Need To Know About The Coming Changes To Medicare Part D?
The Centers for Medicare and Medicaid Services (CMS) released a draft rule to make sweeping changes to the Medicare Part D program in 2015. These proposed changes would have a critical impact on AMCP members, their organizations and their patient populations.
AMCP will host a members-only webinar on the proposed changes in the rule and forthcoming 2015 Medicare Part D call letter. We urge you to attend "What AMCP Members Should Expect in Medicare Part D for 2015: Be the First to Know" on Wednesday, February 26 from 2-3 pm. (Source: AMCP, 1/13/14).
AMCP Members - Take Action NOW!
The Centers for Medicare and Medicaid Services (CMS) released a draft rule to make sweeping changes to the Medicare Part D program in 2015. These proposed changes would have a critical impact on AMCP members, their organizations and their patient populations. AMCP has prepared an extensive summary of the proposed changes, which is available on the AMCP website.The AMCP must take action to ensure that provisions harmful to managed care pharmacy are not enacted. Comments on the proposed rule will be taken by the CMS and are due by March 7, 2014. (Source: AMCP, 1/13/14).
Call For Abstracts - ISPOR 6th Asia Pacific Conference
ISPOR 6th Asia Pacific Conference will take place September 6-9, 2014 in Beijing, China. Check out their new Extended Program and information on Abstract Submission here. Abstract Submission Opens January 20, 2014. (Source: ISPOR, 2014).
What's In Your Pocket? Get IHE In Your Pocket 2014
IHE In Your Pocket is a handbook of Health Economic statistics, designed to provide a compact, comprehensive, and comparative overview of the economic aspects of the Canadian health care system, and has been revised every second year since 2006. The information is put into a multitude of quick and easy to decipher charts and graphs. Read more here. (Source: IHE, 2014).
Ever Wonder About Patented Drug Prices?
The Compendium of Policies, Guidelines and Procedures outlines the process that Board Staff review the prices of patented drug products, and proceed when a price appears to be excessive. This Compendium has been issued to promote awareness and facilitate compliance. More information here. (Source: Patented Medicine Prices Review Board, Reissued June 2013).
Call For Abstracts - ISPOR 19th Annual International Meeting - Deadline This Week!
Abstract Submission Deadline: January 16
ISPOR 19th Annual International Meeting will take place May 31-June 4, 2014, in Montreal, QC, Canada. Abstract submissions are invited for Research abstracts, Workshop proposals, and Issue Panel proposals. Abstract Submission Deadline is JANUARY 16, 2014 with acceptance notifications on March 1, 2014. More information available here. (Source: ISPOR, 2013).
Kaiser Receives $7 Million Grant From PCORI
One of 29 Projects Approved For A Total Of $93.5 Million in grants will come together to form PCORnet: the National Patient-Centered Clinical Research Network, which aims to improve the efficiency of health research. Kaiser Permanente intends to build a clinical data network aimed at improving patient outcomes in cancer, heart disease and obesity. More information here. (Source: HealthcareITNews, 1/10/14).
DIA Call For Professional Posters - Only One Month Left!
The Professional Poster Program is an opportunity for you to present your research to a diverse group of scientific professionals who are actively involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices, and health care related products. Don't miss the Submission Deadline: Monday, February 10. Information on submission requirements here. (Source: DIA, 2013).
FirstWord Pharma PLUS - How Will You Benefit From Upgrading Your Subscription?
Helping professionals stay up-to-date with the most relevant news, insights, analysis, and views from across the globe, this personalized resource provides coverage from over 1,200 international news sources, 2,000 medical journals, 100 medical conferences, 120 regulatory bodies, 13,000 products, 3,500 companies, and 120 medical conditions as well as Physician Views poll data and 7 years' worth of searchable news archives. Subscribe Now! (Source: FirstWord Pharma, 1/12/14).
Check Out This New Website - Canadian Market Access
Get Your Daily Dose Of Reimbursement, Pricing, Health Economics & Government Affairs News. Word is spreading after the successful launch of the new website - Canadian Market Access. Be sure to check them out! (Canadian Market Access, January 2014).
Abacus - Keeping The "New" In The New Year
2014 Brings Exciting Developments To The Abacus International Team. A new Director of Health Technology Assessment, a new Director of Clinical Outcomes Assessment, and a new office opening in London! Abacus is off to a good start in 2014. Read more here. (Source: Abacus International, 2014).
How Can You Prepare For The First Ever HEOR Virtual Career Fair?
Dr. Patti Peeples, CEO and Founder HealthEconomics.com, talks with Klein Hersh Executive Recruiters, Michael Litten and Scott Kabo, about how you can prepare for HE-Xpo's Virtual Career Fair, to help you get the most out of your experience. Listen to Podcast here. (Source: HealthEconomics.com, 2014).
Will HEOR Ever Ditch Pie and Bar Charts? The Rest of the World Is!
Nowadays we are absolutely flooded with data! Many designers are looking at the stagnant charts of the past and feel they don't always work well. This article explores many different ways in which designers are display this overload of information. Take a look here. (Source: Bits, 1/6/14).
Student Pharmacist - AMCP Has A Special Announcement Just For You!
Two selected student pharmacists will spend nine weeks at the Allergan Global Health Outcomes Department in Irvine, Ca.,under the supervision of pharmacist preceptors and will complete a health outcomes-related project. Interns will also spend up to one week at the AMCP Foundation headquarters in Alexandria, Va., where they will be introduced to the workings of professional associations.
Don't miss out on this great opportunity to gain knowledge of the pharmaceutical industry, managed health care systems and professional association management. Apply by the January 17 deadline! (Source: AMCP Foundation, 2013).
A Look Beyond The Price Tag - Why Are New Drugs So Expensive?
We all know that Pharmaceutical R&D is expensive, companies need to be reimbursed for failed investments, fund studies, have money for future developments and the list goes on and on. Is there more to pricing than "what the market will bear?" Read full article here. (Source: MIT Technology Review, 10/22/13).
Healthcare CEOs - Can't Sleep At Night? Try HINs Dream Rx Now!
HIN's ninth annual industry forecast, provides both a handle on what's keeping healthcare CEOs up at night and a dream prescription for sounder program management in 2014. The advice in the 40-page resource is supplemented with data from HIN's tenth annual Healthcare Trends and Forecast survey administered in October 2013. Order your copy of Healthcare Trends & Forcasts in 2014, today! (Source: Health Resources Online, 2013).
PRO Claims - Why Is The EMA Granting More Than The FDA?
There Appears to be poor concordance between the two agencies on the macro level, but upon close examination, there appears to be greater concordance than previously recognized. Full article, Assessment of PRO Label Claims Granted By The FDA As Compared To The EMA (2006-2010) available here. (Source: Elsevier, Dec 2013).
Pharmacoepidemiology Studies - What's New In The EU?
To succesfully conduct an epidemiology study, it is important to understand the environment one is working, the regulatory demands as well as the resources available to conduct these studies. Check out the available resources summarized in this article. (Source: PRM newsletter, Dec 2013).
NICE Extends Role In Value Based Pricing For The NHS
The National Institute for Health and Care Excellence (NICE) will be taking a central role in Value Based Pricing (VBP) for the NHS starting in 2014. To find out more about this, Pharma IQ spoke to NICE's Chief Executive Sir Andrew Dillon about VBP and the challenges that NICE will face in its new extended role. Podcast available here. (Source: PharmaiQ, 9/2/13).
Do Health Outcomes Studies Increase Drug Costs?
The December 17, 2013 newsletter from HealthEconomics.com explored whether the growing need for health outcomes studies will lead to increased research and development costs. Despite the added cost, such studies are growing in demand because they provide data that is not currently addressed by clinical trials. Read more here. (Source: PRWeb, 12/20/13).
GSK's Tafinlar - Will It Reach Germany's Patients?
IQWiG says added benefit of GSK’s Tafinlar not proven. In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…Subscription required to access full article. (Source: thepharmaletter, 1/7/14).
HealthEconomics.com Is Spreading Its Wings - Come Fly With Us!
Expanded Service Offerings Now Include Webinars And Live Streaming Events. The first live streaming event in the HE-Xpo® virtual environment will take place at 11:00am ET on January 9, 2014, and is entitled “Running Successful Trials in Emerging Regions Using Technology to Maximize Success”. For information about participating in HE-Xpo® as an exhibitor and sponsor, contact Leslie Fine, HE-Xpo® Marketing Manager.
Looking For That Perfect Job? Stop Running Around And Sit Down!
The HEOR Career Fair in HE-Xpo® - will run from 9am-1pm ET on January 23, 2014. Exhibitors, job seekers, and employers can interact in a virtual, web-based environment, to showcase jobs, exchange resumes, conduct interviews through real-time chat, and learn effective interview techniques. You can register or read more about this exciting opportunity here! (Source: PRWeb, 12/18/13).
Will You Be Attending The Evidence USA Exhibition In Boston This Year?
Evidence and value development in healthcare is a massive subject with topics ranging from payer engagement, observational research to the use of patient registries and local evidence generation. To breakdown the subject a little more and to give you a guide to some of the main highlights of the Evidence USA exhibition in Boston next October, a simple A-Z of Evidence has been compiled. Download ebook here. (Source: Evidence 2014, 1/2014).
Have You Heard About Evidera's Exciting New Acquisition?
Symphony Technology Group (STG), and Evidera recently announced the acquisition of Archimedes, a San Francisco-based healthcare modeling company and wholly owned subsidiary of Kaiser Permanente. Read more about this exciting new chapter here. (Source: PRNewswire, 1/08/14).
Bayer's Hot-Selling Eylea - Not So Hot Back Home
Sales of Bayer's Eylea have taken off since the EU greenlighted the eye drug in late 2012. But now, Germany's cost watchdog, IQWiG has thrown up a roadblock for the second time. Will Eylea be able to show an advantage over its rival, Novartis' Lucentis? More here. (Source: FiercePharma, 1/3/14).
Bayer's Hot-Selling Eylea - Not So Hot Back Home
Sales of Bayer's Eylea have taken off since the EU greenlighted the eye drug in late in 2012. But now, Germany's cost watchdog, IQWiG has thrown up a roadblock for the second time. Will Eylea be able to show an advantage over its rival, Novartis' Lucentis? More here. (Source: FiercePharma, 1/3/14).
Obamacare - Flashbacks To The Watergate Affair?
The recent "adjustments" made to the ACA, remind this author of the "that statement is no longer operative" line used by the Nixon team, and has him asking "What's next?" Read more. (Source: First Report Managed Care, 1/2/14).
Do You Have A Nomination For The ISPOR 2014 Scientific Awards?
ISPOR's Scientific Awards are designed to recognize outstanding achievements in pharmacoeconomics and outcomes research and will be presented at the ISPOR 19th Annual International Meeting in Montreal, QC, Canada, May 31-June 4, 2014. Nomination requirements and detailed award descriptions can be found at the ISPOR website. If you would like to nominate a candidate or yourself for one of the four awards, please send the required nomination materials to:email@example.com by FRIDAY, FEBRUARY 7, 2014. (Source: ISPOR 2013).
Are JAMA Guidelines Likely To Harm Patients Medically And Financially?
JAMA published the long-awaited Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure-8 (JNC-8)guidelines December 18, 2013. In this article, David Cundiff, MD states that the JNC-8 authors ignored evidence and have put forth guidelines that are potentially harmful and not endorsed by any other authoritative body and calls for a retraction of the guidelines. Read more here. (Source: KevinMD.com, 1/4/14).
Want to stay up-to-date with the latest in HEOR in Latin America?
In this issue of ISPOR Latin America Consortium, you will hear from the General Health Council of Mexico, as they present a useful description of Mexico's decision making process, and read about adopting a cost and resource use measurement instrument to the context of mental health issues in Brazil. The newsletter also features a listing of upcoming congresses and training opportunities, and highlights chapter achievements across Latin America. To view the entire newsletter, click here. (Source: ISPOR Latin America Consortium, Dec 2013).
Key Collaborations Needed to Move beyond the Logical Specialty Pharma Distribution Model
In order to improve distribution effectiveness, quality of care, data collection, and other health information, specialty pharmacies and healthcare groups need to focus on expanding their patient and treatment management services. Building key collaborations with third party health care groups that provide key health information technologies and services that set parameters around guidelines to support a standard of care, treatment pathways and data collection for payers, and the way practices are evaluating the delivery of care. Read more. (Source: Armada, 1/2/2014)
Can GSK Restore Its Reputation After Allegations Of Bribery?
GSK has been in the spotlight this year after being accused of paying almost$500m in bribes to doctors and health officials in China to boost prescribing of its drugs, with the resulting fall-out impacting its third-quarter financial results. Meanwhile, the company paid a massive $3bn settlement in the US in 2012 after pleading guilty to promoting drugs in unapproved uses and making unsupported safety claims for some of its products. Learn more about their new compensation system for reps here. (Source: PMLiVE, 12/17/13).
Can Clinical Trial Recruitment Make It In The Digital World?
There are an increasing number of clinical trial search services popping up, but efforts to harness digital channels for patient recruitment are still at an experimental stage. While more and more patients are going online for health reasons, the potential is obvious, but what is the best way to harness this digital world? Read more here. (Source: PMLiVE, 12/16/13).
Using Carrots and Sticks To Guide Patients To The Care They Truly Need?
Bigger isn't always better, less is sometimes more, and just because it's new doesn't mean it's for you! These are some of the ideas proponents of value based insurance are hoping to spread. About 1/3 of America's healthcare spending is attributed to wasteful or ineffective care. With this new type of insurance, if you want more, bigger and newer procedures-you'll have to pay for them. Read more here. (Source: Reuters, 12/19/13).
Could CER Help Lower Costs Of Specialty Pharmaceuticals?
Specialty pharmaceuticals are complex to manufacture and distribute, often difficult to administer, may require special patient monitoring and are a rapidly growing share of the costs to health plans. Payers are exploring ways to decrease the cost of these drugs; Comparative Effectiveness Research is one tool being discussed. Read more. (Source: NPC, Dec 2013)
Pragmatic Clinical Trails - Finding The Middle Ground
Pragmatic Clinical Trials - The Middle Ground Between Randomized Controlled Trials and Observational Studies
With the Patient-Centered Outcomes Research Institute (PCORI) announcing plans to fund PCTs in 2014, stakeholders are going to be hearing a lot more about this type of research. Learn more about PCTs here. (Source: NPC, Dec 2013)
National Pharmaceutical Council 2013 Year In Review
Since the organization's founding in 1953, NPC's mission has remained the same, but the issues they have chosen to engage in have changed. Take a look back and see what 2013 issues where taken on by NPC, here. (Source: NPC, Dec 2013)
CEA or MCDA - Which Will It Be?
AN ISPOR 16th Annual European Congress - Dublin session - Should Multi-Criteria Decision Analysis (MCDA) Replace Cost Effectiveness Analysis (CER) For Evaluation Of Health Care Coverage Decisions? Click the links below to see individual presentations. (Source: ISPOR 2013).
ISPOR Presents - The Many Perspectives on HTA
AN ISPOR 16th Annual European Congress - Dublin session - Early Engagement Between Manufacturers, HTA Assessors, and Regulators. Click the links below to see individual presentations. (Source: ISPOR 2013).
ISPOR Takes On Cystic Fibrosis
AN ISPOR 16th Annual European Congress - Dublin session - The Patient And Health Technology Assessment: Challenges And Opportunities. Click the links below to see individual presentations. (Source: ISPOR 2013).
ISPOR Presidential Welcome
In his 2013-2014 Presidential Welcome, William Crown, PhD, explains to ISPOR 16th Annual European Congress attendees how ISPOR is making an impact on health care decision making through our tools, best practices, and geographic diversity. Watch video here. (Source: ISPOR, 2013).
How To Run Successful Trials in Emerging Regions
The clinical development world is shrinking and running trials in emerging regions is becoming increasingly desirable and acceptable. This webinar, jointly presented by Pharm-Olam and ERT, will address the challenges most commonly faced by sponsor companies: managing patients, investigative sites, and logistics while implementing technology systems to overcome multi-cultural differences and maximize trial success. Register here. (Source: healtheconomics.com, 12/2013).
Study Finds Inconsistent Use Of Cost-Effectiveness Thresholds
This study looks at fundamental differences between the NHS and the Scottish Medicines Consortium (SMC), raising important policy issues - particularly in regards to the use of QALY thresholds - and then summarizes options in approaching this. Read more here. (Source: OHE, 12/12/13).
How To Use PROs To Compare Providers Fairly
In this article, ADJUSTING PATIENT CASE MIX TO COMPARE PROMS ACROSS PROVIDERS, the authors develop a method of adjusting for case mix that is intended to distinguish when variations in PROMs are the result of variations in the characteristics of patients, rather than variations in treatment success. Learn more here. (Source: OHE, 12/10/13).
Have You Checked Out This ISPOR Distance Learning Program?
Modeling Heath Care Costs - Characteristics of Health Care Costs. This module provides a general view of simple regression analysis with an explanation of why a standard simple approach fails in the estimation of medical costs. Furthermore, an overview of quantitative methods for modeling health care costs will be presented, including propensity score matching, multivariate analysis, and selection bias models. The module includes proposed approaches as well as guidelines to choose among these possible approaches. Learn More Here. (Source: ISPOR, 2013).
Who Said Pharmaceutical Market Access Was Easy?
Pharmaceutical market access is anything BUT easy! Just as you think you understand the rules of the game, they change. Value based pricing anyone? It is perhaps no surprise that the service community is rising to the challenge and offering a range of solutions to help organisations get their treatments to patients. To see a list of these companies and what they can assist you with, Download this ebook, Top Market Access Services Required by Pharma. (Source: totalbiopharma, 11/21/13).
Three Vital Areas for Improving Market Access – for Industry & Payer
Last year’s Pharma Pricing & Market Access Europe included discussions on key topics including: maneuvering changes in the healthcare environment, pricing & market access in the major international markets, and patient access and flexible pricing schemes. One particularly notable presentation was given by Colin Wight, Chief Executive of GalbraithWight, entitled “Three Vital Areas for Improving Market Access – for Industry & Payers” Download this presentation here.
Fixing Moral Issues Behind Clinical Trials
As the cost of clinical trials continues to increase, pharmaceutical companies have chosen only those drugs in which they feel very confident on bringing a return. Often, leaving potentially life saving drugs on the self. How do we get more of these drugs to market at a reduced cost and risk to pharmaceutical companies? Download this ebook, Top Disruptive Innovations in Clinical Trials – 2nd Edition. (Source: totalbiopharma: 11/18/13).
How Can PROs Work For You?
The use of Patient-reported Outcomes is on the rise, and most companies are giving their PRO departments a little extra attention this coming year. Download this presentation given at Evidence 2013, by Ingela Wiklund, UBC, and learn How to Support Product Value Through Patient-reported Outcomes. (Source: UBC, 11/15/13).
Value Based Pricing For Service Level Agreements: The Finale!
Check out Part 3 Of Fabio Cicalini's Case Study: Organizational Transformation. Read Cicalini's Blog For the conclusion of this 3 part, 1 year case study. Read about the new sales and pricing organization, a change in management support, the implementation of a Sales and Pricing Master Class and of course the achievements thus far. (Source: Fabio Cicalini, Pricing2B, 12/14/13).
ISPOR Members - Who Will You Nominate For The Board Of Directors?
Deadline For Nominations Is Friday, January 3!
As an ISPOR member, you are encouraged to submit nominations to serve on the 2014-2015 BOARD OF DIRECTORS. Self-nominations are also permitted. Please email your recommendation to: firstname.lastname@example.org. (Source: ISPOR, 2013).
Utilization Management Of Echocardiography - How Does It Affect Use Across Risk Groups?
This study, conducted by outcomes research company, HealthCore, for AIM Specialty Health, evaluated the impact of an outpatient echocardiography utilization management (UM) program relative to a matched control (non-UM) group by measuring changes in utilization rates overall and within specific cardiac-risk subgroups. For results of this study, read here. (Source: Managed Care, 11/2013).
How Much Do You Really Know About Big Data?
Analytics platforms and new healthcare-specific solutions together are offering far greater insight and intelligence into how healthcare providers are managing patient care, cost, and outcomes. Available as a podcast, on iTunes, full transcript or download here. (Source: ZDNet, 12/12/13).
2013 - Digital Blooms And More
Pharmaceutical Market Europe (PME) - December 2013 Spotlight: Pharmacy in the UK, plus: The IQWIG on comparing medicines, Multi-channel marketing in China, online market research communities, Canada's oncology market, Digital intelligence, R&D pipeline, an innovation update and more…..Read the December issue of PME now. (Source: PMLiVE, December 2013).
University of Birmingham - What's New In HEU?
Check Out The University of Birmingham's Health Economics Unit Newsletter- Winter 2013
The newsletter provides an overview of the current research and teaching activities in the HE Unit. Join in congratulating graduating students, welcoming new students, and read more on student projects and papers here. (Source: University of Birmingham HEU news, Winter 2013).
AMCP Poster Deadline Approaching - Submit Yours Today!
AMCP 26th Annual Meeting & Expo is going to be held in Tampa, FL, April 1-4,2014! Registration is set to open January 14, 2014. The Deadline to submit a poster, however, is quickly approaching - January 2, 2014! (Source: AMCP, 2013).
For more information and to submit a proposal, go here.
PCORI Awards $2M Grant For Clinical Effectiveness Research
The Patient-Centered Outcomes Research Institute has awarded a $2 million grant to a research team from the IU School of Informatics and Computing at Indiana University-Purdue University Indianapolis to conduct comparative clinical effectiveness research. For more information on how the team plans on using the funds to gain a better understanding on how to provide better healthcare for Indiana, read here. (Source: IUPUI, 12/3/13).
Pfizer's Move To Transparancy - Is It Enough?
In response to the growing debate over disclosure of clinical trial data, Pfizer has announced an updated policy and web site that will publish large amounts of information and offer a procedure for independent researchers to obtain study data for analysis. But is it enough? Read here, to find out what the new policy covers, and what it leaves behind. (Source: Pharmalot, 12/4/13).
Is Pharmacy Ready For The Next Revolution?
With well-defined barriers to physician access, the pharma industry is looking towards the pharmacist as a key stakeholder. To help define the interaction that pharma and the pharmacist could have, the latest eyeforpharma whitepaper outlines which companies are leading this new form of customer engagement. (Source: eyeforpharma, 2013).
Download your free copy of The Pharmacist, Tomorrow’s Stakeholder here.
FDA Adverse Event Reporting System - Why Is It Still Inaccessible
The centralized computerized information database for post-marketing drug safety surveillance is the FDA Adverse Event Reporting System (FAERS). Unfortunately, FAERS has remained inaccessible to healthcare professionals. In fact, publicly available FAERS information can only be obtained through complicated data downloads by individuals familiar with….. Read more. (Source: AdverseEvents, The RxView Blog, 12/5/13).
Katie Murphy Lights Up The First Plenary Session Of ISPOR Dublin Meeting
Katie Murphy told over 3,000 audience members about her personal story in the fight against cystic fibrosis (CF), at the first plenary session of the 16th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) European Congress in Dublin. Afterwards she spoke with Pin Lu, from Rx Communications, about what she wanted from health economist and decision makers. Here's what she has to say. (Source: heor.tv, Nov 2013).
Bibliography of Major HEOR Publications, by IMS
IMS Real World Evidence group has released a bibliography of hundreds of relevant publications in the areas spanning major therapeutic areas (CV, Oncology, Asthma, diabetes, etc.) as well health policy, compliance, and more. Great reference source available here. (Source: IMS Health, 2013).
Will The Growing Need For Outcome Studies Lead To Higher Drug Costs?
It used to be that drugs were approved on the basis of their impact on markers of disease, however, over the last decade, long term studies measuring the effect of drugs on ultimate disease outcomes have yielded surprisingly unexpected results. Read more. (Source: Forbes, 12/2/13).
Who's Leading PCORI's Improving Healthcare Systems Program?
The Patient-Centered Outcomes Research Institute has tapped Steven Clauser of the National Cancer Institute to serve as director of its Improving Healthcare Systems Program.Clauser will succeed Dr. Chad Boult, who held the post since October 2012. PCORI, a Washington-based not-for-profit, was...Subscription required to read more.(Source: ModernHealthcare.com, 12/3/13).
What Does Healthcare Look Like In 2014?
From an early surge in Medicare accountable care collaborations to the problematic rollout of the nation's historic health insurance exchanges during a 16-day government shutdown, healthcare in 2013 has been nothing short of unpredictable.
Healthcare Trends & Forecasts in 2014: Performance Expectations for the Healthcare Industry, HIN's ninth annual industry forecast, provides both a handle on what's keeping healthcare CEOs up at night and a dream prescription for sounder program management in 2014. Available for purchases now. (Source: Healthcare Intelligence Network, December, 2013).
Do You Have a Nomination For The Steven G. Avey Award? Don't Miss The Deadline!!
The Academy of Managed Care Pharmacy Foundation is now accepting nominations for the prestigious Steven G. Avey Award. The award recognizes individuals for their distinguished contributions to managed care pharmacy. It will be presented at the Annual Awards Dinner held during AMCP's 26th Annual Meeting & Expo in Tampa, Fl., April 1-4, 2014.(Source: AMCP Foundation, 2013).
Print your nomination form here: the deadline for nominations is January 17, 2014!
Don't Miss This Deadline! Mental Health - Call For Abstracts
DIAGNOSIS, PREVENTION AND TREATMENT IN MENTAL HEALTH: EFFECTIVENESS AND COMPARATIVE EFFECTIVENESS is the second meeting on patient reported outcomes and person centered care in mental health. The meeting will be held September 26-28 2014, in Washington DC. The deadline for abstract submission is March 30, 2014. For more information on this event and details on submission, click here. (Source: International Center of Mental Health Policy and Economics, 2013).
Running Successful Trials in Emerging Regions – Using Technology to Maximize Success
The clinical development world is shrinking and running trials in emerging regions is becoming increasingly desirable and acceptable. This webinar, jointly presented by Pharm-Olam and ERT, will address the challenges most commonly faced by sponsor companies: managing patients, investigative sites, and logistics while implementing technology systems to overcome multi-cultural differences and maximize trial success. Register here. (Source: ERT, 2013).
Whitepaper: Counter Brand Revenue Erosion from Generics through Defensive Pricing Strategies
Defensive pricing is a popular strategy used by pharmaceutical companies to counter threats from low-priced generic alternatives. This whitepaper explores how pricing can effectively support brands facing generic competition. Download here. (Source: Cutting Edge Information, 2013).
Should Surrogate Outcomes Be Used As Proxies For Hard Clinical Outcomes?
Although surrogate outcomes are often used in this way, enabling smaller, faster, cheaper clinical trials; they do have one great disadvantage. To illustrate the perils of relying on surrogates, This report, Surrogate Outcomes in Clinical Trials-A Cautionary Tale, compiles a table of drugs, approved on the basis of surrogate outcome data, which after adoption into practice were shown to be harmful through clinical trials or meta-analyses (eTable). Registration required. (Source: JAMA Internal Medicine 3/25/13).
JGA Call For Papers - Don't Miss This Deadline!
The Journal of Global Analysis (JGA) are inviting manuscript submissions for its upcoming re-launch issue in 2014. Deadline for submissions is March 30,2014. For author requirements and information, please visit JGA's website. (Source: JGA, 2013).
What Does IQWiG Say About Xtandi For Prostate Cancer?
IQWiG says Xtandi has 'major' additional benefit over BSC in patients without visceral metastases and ‘significant’ additional benefit over BSC in patients with visceral metastases. Subscription Required to learn more. (Source: BioCentury, 12/2/13).
Have You Heard - Deep Is The New Big?
This presentation about Data & Analytics: Deep is the New Big; is given by Brian Sweet, Executive Director, AstraZeneca. He discusses why real world evidence is becoming increasingly important for pharma development, major challenges being faced and how they are being tackled, and a detailed case study of a recently ran comparative effectiveness study. Get your FREE Download here. (Source: BigDip Europe, 2013).
Part 2 Of The Case Study, Value Based Pricing for service Level Agreements, has been released.
In his blog, Fabio Cicalini discusses research findings covering; price sensitivity, economic value estimation, the sales' pricing habit, the sales process, and pricing models, including risk sharing. Read more here. (Source: FABIO CICALINI, Pricing2B, 11/30/13).
Have You Heard About OHE's New Services?
OHE Consulting is now offering clients a wide range of analytical and advisory services on health outcomes and the use of patient-reported outcomes (PRO) data. In addition to projects for the pharmaceutical industry on PROs, OHE Consulting also regularly provides advice to health care organisations and governments, in the UK and internationally, on health outcomes measurement and the development of HTA processes. More information here. (Source: OHE, 12/4/13).
What Is The Future Of Value-Based Pricing With ISPOR?
Value-based pricing for pharmaceuticals has been given an implementation deadline of January 1, 2014, but as the this date grows nearer, less and less has been said about it. Many are wondering if VBP will be introduced at all in 2014, and if so, in what form. Full article available here. (Source: IHS Healthcare and Pharma Blog, 11/25/13).
Health Insurance: A Gamble That Goes Both Ways?
Last minute changes to the reform law could expose insurance companies to higher risk. To the insurers, deadline extensions mean a loss of premiums from healthy consumers. How will these changes affect the ratio of healthy and sick consumers? How will insurance companies bottom lines be affected? Read more here. (Source: FierceHealthPayer, 12/5/13).
Smart Glasses - How Might They Change Healthcare?
Smart Glasses, such as Google's glass headset, promise to change the way we interact with technology. How could this change healthcare you might ask, it seems the possibilities are endless. Read more here and find out what Dr Christopher Kaeding, a surgeon at the Ohio State University Wexner Medical Center, had to say after using Glass to stream video during a knee operation. (Source: PMLiVE, 12/4/13).
Brand Planning - Who's On Your Team?
In this article, Jan Steele PhD, operations director at Lucid, discusses the idea of running a parallel planning process that will, in the long run, save time. How would this be set up? Who should be included? What are the benifits? Read her full article here and find out. (Source: PMLiVE, 12/5/13).
NICE Lower Threshold Research - What Does Ulf Stagginus Have To Say About?
Surprised by OHE's recent critique, Stagginus gives his own response - short and sweet…well, maybe not so much sweet! Ulf tells it like it is here! (Source: Ulf Stagginus, Health Economics Blog, 12/4/13).
The Very Active Oncology Pipeline
In the past 3 years, approximately one-third of drugs the FDA has approved have been intended to treat cancer. The trend is expected to continue for the foreseeable future, as oncology is the leading category of pharmaceuticals in the pipeline. Burt Zweigenhaft, chief executive officer of Onco360, spoke at the NASP meeting during a session titled The Future of the Specialty Pharmacy Pipeline: Trends & Key Areas to Watch. He noted that there are several reasons for the increasing number of oncology drugs, including that the incidence of cancer is rising, more people are surviving with the disease, and therapies have become more effective. Read more from his presentation here. (Source: First Report Managed Care, 11/7/2013)
Market Access & Reimbursement Information in Specialty Rx Prescription Decisions has Many Challenges
Jayne Hornung, RPh, vice president/pharmacy and medical data for Managed Markets Insight & Technology noted at the NASP meeting that "It is a broken system". Dr. Hornung noted the many challenges that exist throughtout the healthcare system during her session. Read more about research Managed Markets Insight & Technology performed on coverage of disease-modifying antirheumatic drugs (DMARDs) for treating rheumatoid arthritis here. (Source: First Report Managed Care, 11/7/13)
Is A Lack Of Transparency Weakening Evidence-Based Medicine?
A recent study found only half of all drug studies recorded in a large Web-based, federal registry, ClinicalTrials.gov had been published in a journal. Of these published trials, most were not in a timely manner, and many contained only selective information, leaving out such things as "adverse events" and "serious adverse events". How does this affect well-informed decision making about patients' health, and what needs to be done to fix this? Read more here. (Source: Medical Daily, 12/3/13).
Should NICE Lower Cost-Per-QALY Threshold?
The OHE recently published an Occasional Paper by Barnsley et al that counters the recently-published recommendation by Claxton et al that NICE should lower its cost-per-QALY threshold from the current £20,000–£30,000 official range to £12,936. Learn more about the difficulties the Barnsley critique sees in this proposal here. (Source: OHE, 12/2/13).
Michael J. Fox to Keynote Specialty Pharmacy Summit
Armada Health Care has announced that Michael J. Fox will keynote the 10th Annual Specialty Pharmacy Summit & Expo. Best known for his acting, Fox is now an author, speaker and spokesperson for The Michael J. Fox Foundation for Parkinson's Research. The Summit takes place at the Wynn Hotel in Las Vegas on May 5-9, 2014. More information here. (Source: Armada, 11/20/13)
Is Public Opinion About The Affordable Care Act Changing?
So, we've all heard about the web site glitches and stories about individuals being dropped from their insurance plans; things don't seem to be moving quite as smoothly as some had hoped! How are these "disruptions" affecting the public's view on the law? Read about the results from this tracking poll conducted by the Kaiser Foundation. (Source: First Report Managed Care, 11/26/13).
Does HIN See Future Growth In The ACO Movement?
According to their findings, the ACO movement shows no signs of slowing down. This 65-page, 2013 Healthcare Benchmarks: Accountable Care Organizations, is part of the HIN Healthcare Benchmarking series. Order yours today! (Source: Health Resources Online, 11/2013).
Have You Checked Out The ISPOR Distance Learning Program?
Now available for purchase through the ISPOR Distance Learning Program (iDLP), Modeling Health Care Costs-Characteristics of Health Care Costs. This module provides a general view of simple regression analysis with an explanation of why a standard simple approach fails in the estimation of medical costs. Learn more. (Source: ISPOR, 2013).
How Is Pharma Responding To The Informed Patient Movement?
This FirstWord Report, Patient-Centricity: Solving the latest pharma puzzle, explores the myriad unknowns of patient empowerment and provides a critical overview that aims to establish a broad consensus, best practices and insight into how to integrate patient-centricity into the pharma business model. Purchase required. (Source: FirstWord, 7/2013).
HIN's Healthcare Trends & Forecasts in 2014 - Have You Ordered Your Copy?
HIN's ninth annual industry forecast - Healthcare Trends & Forecasts in 2014: Performance Expectations for the Healthcare Industry - is a highly respected and anticipated resource highlighting the challenges that will continue to consume the healthcare executive in the year ahead and provides both a handle on what's keeping healthcare CEOs up at night and a dream prescription for sounder program management in 2014. Check here for more information or to reserve your copy today! (Source: HIN, 2013).
Are You A Member Of The ACO Learning Network Yet? Submit Your Member Form Today!
The Learning Network is a fees-based, member-driven organization that provides members the tools and knowledge to effectively implement accountable care in all parts of the country. They have an exciting year planned that will provide you with numerous ways to engage with and learn alongside your colleagues -- webinars, in-person conferences, innovation exchanges focused on implementation and policy issues, online resources, and ongoing research with external stakeholders. More information on becoming a member available here. (Source: ACO Learning Network, 11/20/13).
Specialty Pharmacy Summit & Expo - Don't Miss The Early Bird Rate!
The 10th Annual Specialty Pharmacy Summit & Expo is scheduled for May 5-9, 2014, in Las Vegas! Early bird rates will expire on December 31,2013. Hosted by Armada Health Care, the conference recently announced Michael J. Fox as their 2014 Keynote Speaker! Additional conference details, exhibitor/sponsor registration and other information available here. (Armada Health Care, 2013).
What Makes a Specialty Pharmacy Stand Out From the Others?
Avella believes their commitment to excellence sets them apart, and every department at Avella shares this commitment. At the center of everything they do is the patient, and a focus on positively impacting their lives. Learn what excellence means to Avella in these videos, featuring members of the Avella team. (Source: Avella Specialty Pharmacy, 2013).
OHE Study Extended to 2018 - What Do UK Medicine Expenditures Look Like?
OHE’s model for projecting NHS medicines expenditure was an important tool used by the Association of the British Pharmaceutical Industry (ABPI) to produce its forecast for discussion with the Department of Health. OHE extended the model published in PharmacoEconomics to cover the evolution of NHS medicines expenditure until the end of 2018. More Information here. (Source: Office of Health Economics, 11/18/13).
What Do The Experts Think About Obamacare?
Here, Dr. Jonathan P. Weiner, Professor of Health Policy & Management at the Johns Hopkins Bloomberg School of Public Health attempts to explain some aspects of the Affordable Care Act and tells us what he thinks about it. Read more. (Source: abc2new.com, 11/14/13).
A Biopharmaceutical Adventure - To The Pill and Beyond!
A shift in marketing is taking Biopharmaceutical companies from developing and selling pills to also developing value-added services in an effort to gain a competitive advantage. How are companies navigating this new frontier? Will the help of external partners be needed? Will we see a price tag attached to these services in the future? Read here for more information. (Source: PMLiVE, 11/18/13).
Who Has Obama Nominated As New Surgeon General?
Obama recently nominated Dr. Vivek H. Murthy as surgeon general. Murthy, an early supporter and grass-roots advocate for the Affordable Care Act, worked to help elect Obama in 2008 as part of a group known as Doctors for Obama. Read full article here to learn more about Dr Muthy and this nomination. (Source: New York Times, 11/14/13).
Thomas Jefferson University Launches New Program!
Jefferson School of Population Health’s innovative graduate programs are equipping a new generation of healthcare professionals to lead the way in the evolving healthcare landscape. Their 15-credit academic certificate program in population health keeps you ahead of the curve, or if you prefer a less intensive option, the Professional Development Academy will provide you with an overview of the basic concepts. A free informational webinar was held for each program on Wednesday November 20, 2013, and is still available!
View the online information session about the certificate program here.
View the online information session about the Professional Development Academy here.
Confounding and Missing Data in Cost-Effectiveness Analysis: Comparing different methods
Grant Opportunity: Infrastructure Development Program in PCORI
Deadline December 20, 2014
WP243 Thought Leader Compensation: US vs. EU
Global strategies for establishing fair-market value payments for opinion leaders can prove challenging. This white paper provides a guidepost to determine European fee schedules and compensation limits. It also outlines the differences observed between US and EU hourly rates. (Source: Cutting Edge Information)
Read more. (Note: form must be completed to download)
Read more. (Note: form must be completed to download)